Please login to the form below

Not currently logged in
Email:
Password:

Eric Rhodes becomes CEO of ERS Genomics

Succeeds the company’s founder Shaun Foy in the role

ERS Genomics Eric RhodesERS Genomics, an Irish biotechnology firm, has appointed Eric Rhodes as its new chief executive officer.

He replaces co-founder Shaun Foy in the lead role, who will continue on with the company as chairman of the board.

Rhodes joins ERS Genomics from Horizon Discovery, where he served as senior vice president of research and development and chief technology officer.

In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development.

Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo Biosciences.

Foy said: “With his deep understanding of the gene-editing landscape and extensive experience in marketing and commercialising gene-editing technologies, Eric is a perfect fit to help ERS Genomics accelerate our commercialisation activities.

“We are excited to welcome him to the team.”

10th June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics